Shay Shemesh
Fundador en NUVECTIS PHARMA, INC. .
Fortuna: 10 M $ al 30/04/2024
Cargos activos de Shay Shemesh
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
NUVECTIS PHARMA, INC. | Director de Operaciones | 27/07/2020 | - |
Fundador | 27/07/2020 | - | |
Corporate Officer/Principal | 27/07/2020 | - |
Historial de carrera de Shay Shemesh
Antiguos cargos conocidos de Shay Shemesh.
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
STEMLINE THERAPEUTICS, INC. | Director Técnico/Científico/I+D | 01/01/2015 | 01/01/2020 |
Consejero General | 01/01/2015 | 01/01/2020 | |
KERYX BIOPHARMACEUTICALS | Director Técnico/Científico/I+D | - | - |
Formación de Shay Shemesh.
Bar-Ilan University | Graduate Degree |
Estadísticas
Internacional
Estados Unidos | 4 |
Israel | 2 |
Operativa
Chief Tech/Sci/R&D Officer | 2 |
Chief Operating Officer | 1 |
Founder | 1 |
Sectorial
Health Technology | 4 |
Consumer Services | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas cotizadas | 1 |
---|---|
NUVECTIS PHARMA, INC. | Health Technology |
Empresas privadas | 2 |
---|---|
Stemline Therapeutics, Inc.
Stemline Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, acquisition, development, and commercialization of novel therapeutics for oncology indications of unmet medical need. Its clinical stage product candidates include SL-401, SL-801, and SL-701. The SL-401, is a targeted therapy directed to the interleukin-3 receptor (CD123) present on a malignancies. The SL-801, is a novel oral small molecule reversible inhibitor of XPO1, that has demonstrated in vivo and in vitro preclinical activity in solid and hematologic malignancies. The SL-701, is an immunotherapy designed to activate the immune system to attack tumors. The company was founded by Ivan Bergstein on August 8, 2003 and is headquartered in New York, NY. | Health Technology |
Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Keryx Biopharmaceuticals, Inc. engaged in the manufacture, development, and commercialization of medicines for use in treating human diseases. The company was founded in August 1, 2002 and was headquartered in Cambridge, MA. | Health Technology |
- Bolsa de valores
- Insiders
- Shay Shemesh
- Experiencia